Evidence map›Paper›PMID 39450860›Full record

ArticleNeuro-oncology2025

Prospective longitudinal analysis of physiologic MRI-based tumor habitat predicts short-term patient outcomes in IDH-wildtype glioblastoma.

Hye Hyeon Moon, Ji Eun Park, NakYoung Kim, Seo Young Park, Young-Hoon Kim, Sang Woo Song, Chang Ki Hong, Jeong Hoon Kim, Ho Sung Kim

Abstract read
In one paragraph

Article in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hye Hyeon MoonDepartment of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.ORCID 0000-0001-8484-3117
Ji Eun ParkDepartment of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.ORCID 0000-0002-4419-4682
NakYoung KimDynapex LLC., Seoul, Republic of Korea.ORCID 0000-0001-8756-8587
Seo Young ParkDepartment of Clinical Epidemiology and Biostatistics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.ORCID 0000-0002-2702-1536
Young-Hoon KimDepartment of Neurosurgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.ORCID 0000-0002-8852-6503
Sang Woo SongDepartment of Neurosurgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.ORCID 0000-0002-5523-3798
Chang Ki HongDepartment of Neurosurgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.ORCID 0000-0002-2761-0373
Jeong Hoon KimDepartment of Neurosurgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.ORCID 0000-0001-7131-4523
Ho Sung KimDepartment of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.ORCID 0000-0002-9477-7421

Funding

Korea Health Industry Development InstituteKorean government RS-2023-00208227Ministry of Health & Welfare, Republic of Korea HI22C1723National Research Foundation of Koreathe Korea Health Technology R&D Project
6 · The paper itself

Abstract

backgroundThis study validates MRI-based tumor habitats in predicting time-to-progression (TTP), overall survival (OS), and progression sites in isocitrate dehydrogenase (IDH)-wildtype glioblastoma patients.

methodsSeventy-nine patients were prospectively enrolled between January 2020 and June 2022. MRI, including diffusion-weighted and dynamic susceptibility contrast imaging, were obtained immediately postoperation and at three serial timepoints. Voxels from cerebral blood volume and apparent diffusion coefficient maps were grouped into three habitats (hypervascular cellular, hypovascular cellular, and nonviable tissue) using k-means clustering. Predefined cutoffs for increases in hypervascular and hypovascular cellular habitat were applied to calculate the habitat risk score. Associations between spatiotemporal habitats, habitat risk score, TTP, and OS were investigated using Cox proportional hazards modeling. Habitat risk score was compared to tumor volume using time-dependent receiver operating characteristics analysis. Progression sites were matched with spatial habitats.

resultsIncreases in hypervascular and hypovascular cellular habitats and habitat risk scores were associated with shorter TTP and OS (all P < .05). Hypovascular cellular habitat and habitat risk scores 1 and 2 independently predicted TTP (hazard ratio [HR], 4.14; P = .03, HR, 4.51; P = .001 and HR, 10.02; P < .001, respectively). Hypovascular cellular habitat and habitat risk score 2 independently predicted OS (HR, 4.01, P = .003; and HR, 3.27, P < .001, respectively). Habitat risk score outperformed tumor volume in predicting TTP (12-month AUC, 0.762 vs. 0.646, P = .048). Hypovascular cellular habitat predicted progression sites (mean Dice index: 0.31).

conclusionsMultiparametric physiologic MRI-based spatiotemporal tumor habitats and habitat risk scores are useful biomarkers for early tumor progression and outcomes in IDH-wildtype glioblastoma patients.

Indexed as

Brain NeoplasmsGlioblastomaIsocitrate DehydrogenaseMagnetic Resonance ImagingAdultAgedDisease ProgressionFemaleFollow-Up StudiesHumansLongitudinal StudiesMaleMiddle AgedPrognosisProspective StudiesSurvival RateIsocitrate Dehydrogenasegliomaisocitrate dehydrogenasemagnetic resonance imagingoutcometumor habitat

Identifiers

PMID39450860
PMCPMC11889713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.